Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.48
EW's Cash to Debt is ranked higher than
73% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. EW: 2.48 )
EW' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 2.48

Equity to Asset 0.58
EW's Equity to Asset is ranked higher than
67% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EW: 0.58 )
EW' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.74
Current: 0.58

0.37
0.74
Interest Coverage 46.38
EW's Interest Coverage is ranked higher than
61% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. EW: 46.38 )
EW' s 10-Year Interest Coverage Range
Min: 1.04   Max: 9999.99
Current: 46.38

1.04
9999.99
F-Score: 5
Z-Score: 8.89
M-Score: -4.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.45
EW's Operating margin (%) is ranked higher than
92% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.93 vs. EW: 20.45 )
EW' s 10-Year Operating margin (%) Range
Min: -29.23   Max: 22.84
Current: 20.45

-29.23
22.84
Net-margin (%) 34.70
EW's Net-margin (%) is ranked higher than
98% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. EW: 34.70 )
EW' s 10-Year Net-margin (%) Range
Min: -33.83   Max: 19.15
Current: 34.7

-33.83
19.15
ROE (%) 46.87
EW's ROE (%) is ranked higher than
99% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.73 vs. EW: 46.87 )
EW' s 10-Year ROE (%) Range
Min: -32.69   Max: 25.78
Current: 46.87

-32.69
25.78
ROA (%) 26.66
EW's ROA (%) is ranked higher than
99% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. EW: 26.66 )
EW' s 10-Year ROA (%) Range
Min: -21.38   Max: 15.84
Current: 26.66

-21.38
15.84
ROC (Joel Greenblatt) (%) 56.46
EW's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. EW: 56.46 )
EW' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -168.46   Max: 63.32
Current: 56.46

-168.46
63.32
Revenue Growth (%) 14.00
EW's Revenue Growth (%) is ranked higher than
89% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EW: 14.00 )
EW' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 14
Current: 14

0
14
EBITDA Growth (%) 24.00
EW's EBITDA Growth (%) is ranked higher than
91% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. EW: 24.00 )
EW' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 28
Current: 24

0
28
EPS Growth (%) 23.40
EW's EPS Growth (%) is ranked higher than
89% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EW: 23.40 )
EW' s 10-Year EPS Growth (%) Range
Min: 0   Max: 348.1
Current: 23.4

0
348.1
» EW's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

EW Guru Trades in Q4 2013

Pioneer Investments 179,470 sh (New)
Vanguard Health Care Fund 5,324,000 sh (+306.07%)
Joel Greenblatt 117,760 sh (+278.76%)
PRIMECAP Management 280,000 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham 67,987 sh (-5.97%)
Ron Baron 1,533,972 sh (-29.66%)
Jim Simons 188,800 sh (-33.03%)
Steven Cohen 3,398 sh (-99.33%)
» More
Q1 2014

EW Guru Trades in Q1 2014

Paul Tudor Jones 101,400 sh (New)
Steven Cohen 13,278 sh (+290.76%)
Pioneer Investments 256,068 sh (+42.68%)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 5,324,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Jim Simons Sold Out
Ron Baron 1,354,511 sh (-11.7%)
Jeremy Grantham 53,446 sh (-21.39%)
Joel Greenblatt 71,689 sh (-39.12%)
» More
Q2 2014

EW Guru Trades in Q2 2014

Jim Simons 19,300 sh (New)
Joel Greenblatt 259,073 sh (+261.38%)
Jeremy Grantham 167,446 sh (+213.3%)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 4,920,000 sh (-7.59%)
Ron Baron 1,083,004 sh (-20.04%)
Pioneer Investments 203,209 sh (-20.64%)
Paul Tudor Jones 5,000 sh (-95.07%)
» More
Q3 2014

EW Guru Trades in Q3 2014

Vanguard Health Care Fund 4,207,470 sh (-14.48%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Reduce -14.48%0.16%$84.44 - $104.02 $ 120.2827%4207470
Joel Greenblatt 2014-06-30 Add 261.38%0.2%$72.97 - $87.86 $ 120.2848%259073
Ron Baron 2014-06-30 Reduce -20.04%0.08%$72.97 - $87.86 $ 120.2848%1083004
Joel Greenblatt 2014-03-31 Reduce -39.12%0.07%$64.17 - $73.93 $ 120.2874%71689
Vanguard Health Care Fund 2013-12-31 Add 306.07%0.83%$61.44 - $78.14 $ 120.2878%5324000
Ron Baron 2013-12-31 Reduce -29.66%0.21%$61.44 - $78.14 $ 120.2878%1533972
Joel Greenblatt 2013-12-31 Add 278.76%0.13%$61.44 - $78.14 $ 120.2878%117760
Ray Dalio 2013-12-31 Sold Out 0.02%$61.44 - $78.14 $ 120.2878%0
Joel Greenblatt 2013-09-30 Reduce -26.19%0.03%$65.25 - $73.4 $ 120.2871%31091
Ray Dalio 2013-09-30 New Buy0.02%$65.25 - $73.4 $ 120.2871%25695
Ron Baron 2013-06-30 Add 135.69%0.4%$62.54 - $84.93 $ 120.2869%1985766
Meridian Funds 2013-06-30 Add 33.69%0.33%$62.54 - $84.93 $ 120.2869%506700
Vanguard Health Care Fund 2013-06-30 New Buy0.32%$62.54 - $84.93 $ 120.2869%1311100
Joel Greenblatt 2013-06-30 Add 526.16%0.1%$62.54 - $84.93 $ 120.2869%42122
Meridian Funds 2013-03-31 Add 11.14%0.11%$78.66 - $94.56 $ 120.2837%379000
Joel Greenblatt 2013-03-31 Add 35.68%0.01%$78.66 - $94.56 $ 120.2837%6727
Meridian Funds 2012-12-31 Reduce -37.67%0.79%$83.7 - $109.75 $ 120.2834%341000
Ron Baron 2012-12-31 Reduce -20.52%0.15%$83.7 - $109.75 $ 120.2834%828833
Joel Greenblatt 2012-12-31 New Buy0.03%$83.7 - $109.75 $ 120.2834%4958
PRIMECAP Management 2012-09-30 New Buy0.05%$97.37 - $108.72 $ 120.2818%300000
Richard Perry 2012-06-30 Sold Out 0.04%$68.5 - $102.97 $ 120.2843%0
PRIMECAP Management 2012-06-30 Sold Out 0.03%$68.5 - $102.97 $ 120.2843%0
Ron Baron 2012-03-31 Reduce -42.37%0.42%$68.43 - $82.67 $ 120.2874%1228628
Meridian Funds 2012-03-31 Add 52.76%0.41%$68.43 - $82.67 $ 120.2874%564749
Richard Perry 2012-03-31 New Buy0.04%$68.43 - $82.67 $ 120.2874%10700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.10
EW's P/E(ttm) is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 51.70 vs. EW: 17.10 )
EW' s 10-Year P/E(ttm) Range
Min: 11.18   Max: 3625
Current: 17.1

11.18
3625
P/B 6.70
EW's P/B is ranked higher than
55% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. EW: 6.70 )
EW' s 10-Year P/B Range
Min: 2.76   Max: 8.46
Current: 6.7

2.76
8.46
P/S 6.20
EW's P/S is ranked higher than
58% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. EW: 6.20 )
EW' s 10-Year P/S Range
Min: 2.11   Max: 7.38
Current: 6.2

2.11
7.38
PFCF 12.00
EW's PFCF is ranked higher than
96% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 12.00 )
EW' s 10-Year PFCF Range
Min: 7.81   Max: 534.25
Current: 12

7.81
534.25
EV-to-EBIT 27.57
EW's EV-to-EBIT is ranked higher than
77% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 34.56 vs. EW: 27.57 )
EW' s 10-Year EV-to-EBIT Range
Min: 11.9   Max: 69.5
Current: 27.57

11.9
69.5
PEG 1.16
EW's PEG is ranked higher than
97% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 1.16 )
EW' s 10-Year PEG Range
Min: 0.78   Max: 3.5
Current: 1.16

0.78
3.5
Shiller P/E 38.70
EW's Shiller P/E is ranked higher than
87% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 38.70 )
EW' s 10-Year Shiller P/E Range
Min: 25.28   Max: 69.38
Current: 38.7

25.28
69.38
Current Ratio 4.21
EW's Current Ratio is ranked higher than
82% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. EW: 4.21 )
EW' s 10-Year Current Ratio Range
Min: 0.89   Max: 4.99
Current: 4.21

0.89
4.99
Quick Ratio 3.63
EW's Quick Ratio is ranked higher than
85% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. EW: 3.63 )
EW' s 10-Year Quick Ratio Range
Min: 0.49   Max: 4.1
Current: 3.63

0.49
4.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 176.90
EW's Price/Net Cash is ranked higher than
83% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 176.90 )
EW' s 10-Year Price/Net Cash Range
Min: 129.21   Max: 129.21
Current: 176.9

Price/Net Current Asset Value 26.70
EW's Price/Net Current Asset Value is ranked higher than
78% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 26.70 )
EW' s 10-Year Price/Net Current Asset Value Range
Min: 19.52   Max: 309.23
Current: 26.7

19.52
309.23
Price/Tangible Book 8.50
EW's Price/Tangible Book is ranked higher than
61% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.00 vs. EW: 8.50 )
EW' s 10-Year Price/Tangible Book Range
Min: 5.57   Max: 188.29
Current: 8.5

5.57
188.29
Price/DCF (Projected) 2.00
EW's Price/DCF (Projected) is ranked higher than
86% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 456.50 vs. EW: 2.00 )
EW' s 10-Year Price/DCF (Projected) Range
Min: 1.35   Max: 3.62
Current: 2

1.35
3.62
Price/Median PS Value 2.00
EW's Price/Median PS Value is ranked higher than
55% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. EW: 2.00 )
EW' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2.24
Current: 2

0.4
2.24
Price/Peter Lynch Fair Value 1.20
EW's Price/Peter Lynch Fair Value is ranked higher than
97% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 1.20 )
EW' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.88   Max: 3.89
Current: 1.2

0.88
3.89
Price/Graham Number 2.50
EW's Price/Graham Number is ranked higher than
82% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 7.03 vs. EW: 2.50 )
EW' s 10-Year Price/Graham Number Range
Min: 1.84   Max: 33.82
Current: 2.5

1.84
33.82
Earnings Yield (Greenblatt) 3.60
EW's Earnings Yield (Greenblatt) is ranked higher than
76% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. EW: 3.60 )
EW' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.4
Current: 3.6

1.4
8.4
Forward Rate of Return (Yacktman) 15.58
EW's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.44 vs. EW: 15.58 )
EW' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 28.3
Current: 15.58

3.1
28.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EWL.Germany
Edwards Lifesciences Corporation was incorporated in Delaware on September 10, 1999. It is a provider of products and technologies designed to treat advanced cardiovascular disease. The Company is focused specifically on technologies that treat structural heart disease and critically ill patients. Cardiovascular disease is the number-one cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individual's entire circulatory system. In its later stages, cardiovascular disease is frequently treated by surgical interventions. The products and technologies provided by the Company to treat advanced cardiovascular disease are categorized into four main areas: Heart Valve Therapy; Critical Care; Cardiac Surgery Systems; and Vascular. The Company's Heart Valve Therapy portfolio is comprised of tissue heart valves and heart valve repair products. Tissue heart valves and repair products are used to replace or repair a patient's diseased or defective heart valve. In the Critical Care area, the Company is a provider of hemodynamic monitoring equipment used to measure a patient's cardiovascular function and in disposable pressure transducers, and also provides central venous access products for fluid and drug delivery. The Company's Cardiac Surgery Systems portfolio comprises a diverse line of products for use during cardiac surgery including cannula, EMBOL-X technologies, and other disposable products used during cardiopulmonary bypass procedures. In December 2007, the Company acquired the CardioVations line of products used in MIS. The Company's Vascular portfolio includes a line of balloon catheter-based products, surgical clips and inserts, artificial implantable grafts, and stents for which approval is being sought for use in treatment of peripheral vascular disease. It operates manufacturing facilities in a number of geographies around the world. It maintains heart valve manufacturing facilities in California, Switzerland, and Singapore. Critical Care products are manufactured mainly in the Company's facilities located in Puerto Rico and the Dominican Republic. Edwards' Cardiac Surgery Systems and Vascular products are manufactured mainly in Utah and Puerto Rico, respectively. The Company sold the LifeStent product line in January 2008, but would continue to manufacture these products for the buyer until the earlier of mid-2010 or the transfer of manufacturing to the buyer. The healthcare marketplace continues to be competitive with strong global and local competitors. The Company competes with many companies, ranging from small start-up enterprises to companies that are larger and more established than it with access to financial resources. Furthermore, rapid product development and technological change characterize the market in which the Company competes. The Company's primary competito
» More Articles for EW

Headlines

Articles On GuruFocus.com
East West Petroleum Announces Results of Annual General Meeting Oct 15 2014 
EW: Potential for Capital Appreciation Oct 03 2014 
Outperform with Historical Low P/B Portfolios Sep 12 2014 
Weekly 52-Week Highs Highlight: HNP, HDB, MMC, EW Aug 31 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
Ron Baron's Favorite Stocks Jun 28 2013 
Ron Baron's Market Strategy - CNBC Interview Jun 28 2013 
Guru Stocks at 52-Week Lows: EC, OKS, LFL, LINE, EW May 06 2013 
Insider Buys at 52-Week Lows May 04 2013 

More From Our Partners
Edwards Lifesciences Shares Up Sharply Following Earnings Beat Oct 24 2014 - BENZINGA

More From Other Websites
Insider Trading Alert - EW, SLAB And LCI Traded By Insiders Oct 30 2014
Can the Rally in Edwards Lifesciences (EW) Shares Continue? Oct 28 2014
Unexpected Obamacare boost Oct 27 2014
Health care stocks hitting new highs Oct 27 2014
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% Oct 27 2014
Friday's market movers: EW, PG & more Oct 24 2014
Stocks Hold Near Session Highs; Drugmakers Shine Again Oct 24 2014
Edwards Lifesciences Hits New High On Q3 Earnings Oct 24 2014
Edwards Lifesciences (EW) Stock Is Up Double Digits Today After Raising Full Year Forecast Oct 24 2014
Edwards Lifesciences Tops Q3 Earnings, Revenues; Ups View Oct 24 2014
RTI Surgical (RTIX) Jumps: Stock Moves 12.6% Higher Oct 24 2014
Edwards ups '14 EPS outlook Oct 23 2014
Cramer: This stock is cheap Oct 23 2014
Edwards Lifesciences Corp Earnings Call scheduled for 5:00 pm ET today Oct 23 2014
Edwards Lifesciences beats Street 3Q forecasts Oct 23 2014
Edwards Lifesciences beats Street 3Q forecasts Oct 23 2014
EDWARDS LIFESCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 23 2014
[$$] Edwards Lifesciences Profit Rises 23% Oct 23 2014
Edwards Lifesciences Reports Third Quarter Results Oct 23 2014
Edwards 3rd quarter net rises 23 pct, 2014 outlook increased Oct 23 2014
The Zacks Analyst Blog Highlights: Edwards Lifesciences, Hospira, Hologic and Heartware... Oct 23 2014
Q3 2014 Edwards Lifesciences Corp Earnings Release - After Market Close Oct 23 2014
Can Edwards Lifesciences (EW) Surprise Earnings in Q3? Oct 22 2014
Allergan CEO resigns from Edwards Lifesciences' board Oct 03 2014
Edwards shares rise on new heart valve approval Jun 17 2014
Medtronic to pay $1B-plus in patent settlement May 20 2014
Edwards Lifesciences Comments on U.S. Appeals Court Order Apr 21 2014
Edwards jumps after injunction against Medtronic Apr 14 2014
US STOCKS-Futures tick up after Citi earnings; eyes on Ukraine Apr 14 2014
Lions Gate and Prana are big market movers Mar 31 2014
Edwards Lifesciences Announces First Human Implants With Mitral Transcatheter Valve System Mar 06 2014
Edwards' SAPIEN XT Valve Approved in Europe for Transcatheter Mitral and Aortic Valve-in-Valve... Feb 05 2014
Edwards Lifesciences to Host Earnings Conference Call on February 3, 2014 Jan 21 2014
Jury says Medtronic owes Edwards about $390M Jan 15 2014
Federal Jury Finds Medtronic CoreValve Willfully Infringes Edwards' Transcatheter Valve Patent Jan 15 2014
Edwards to Begin U.S. Trial of SAPIEN 3 Valve for Intermediate Risk Patients Jan 13 2014
Edwards Lifesciences to Present at the 32nd Annual J.P. Morgan Healthcare Conference Jan 09 2014
MELA Sciences Appoints Healthcare Executive Jeff O’Donnell as Director and Streamlines Board to... Jan 08 2014
The Edwards Lifesciences Fund to Grant ~$5.6 Million to 450+ Non-Profit Organizations in 2013 Dec 06 2013
Edwards Lifesciences Announces Appointment of CFO Dec 05 2013
Edwards Comments on German Appellate Court Ruling Nov 14 2013
Edwards Lifesciences Expands Singapore Manufacturing Facility Nov 13 2013
US close: Stocks grind higher heading into month-end Oct 30 2013
Edwards Lifesciences to Webcast Analyst Meeting at TCT 25 Oct 28 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK